Thiazolyl Benzenesulfonamide Derivative as a Novel Inhibitor of Thymidine Kinase: Promising Therapeutics Against Staphylococcus aureus
Chemistry & Biodiversity · 2025
DOI: 10.1002/cbdv.202501600 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemistry & Biodiversity, 2025. Verfasst von Rajesh K Hadiya und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological Sciences & Engineering, Indian Institute of Technology Gandhinagar, Palaj, Gandhinagar, Gujarat, India. Hauptthemen laut MEDLINE: Staphylococcus aureus, Sulfonamides, Anti-Bacterial Agents, Thiazoles. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Indian Council of Medical Research-Department of Health Research, Indian Council of Medical Research.
Abstract (Originalsprache)
The emergence of multidrug‐resistant Staphylococcus aureus necessitates novel antimicrobial strategies. This study reports the synthesis and evaluation of thiazolyl benzenesulfonamide‐derived synthetic kinase inhibitors targeting thymidine kinase (TK), essential for bacterial DNA metabolism. Derivatives were synthesized via aromatic ring modifications and characterized by 1 H/ 13 C NMR. Compound DSA3 exhibited significant interaction with TK. Fluorescence binding assays confirmed high‐affinity DSA3–TK binding, corroborated by isothermal titration calorimetry revealing exothermic, spontaneous complex formation (favorable Δ G , Δ H , Δ S ). Molecular docking positioned DSA3 within the TK ATP‐binding pocket, forming hydrogen bonds and hydrophobic contacts with key residues, including the catalytic residue Glu89. Molecular dynamics simulations indicated DSA3 stabilizes TK structure by inducing minimal conformational perturbation. Crucially, DSA3 potently inhibited the ATPase activity of TK with an IC 50 value of 6.99 µM, disrupting its enzymatic function. In vitro antimicrobial testing showed the MIC value of 50 µM, demonstrating the potent activity of DSA3 against S. aureus (ATCC 29213). These integrated findings validate DSA3 as a promising TK inhibitor, effectively impeding bacterial growth by targeting DNA synthesis. This highlights the potential of DSA3 as a novel therapeutic agent against multidrug‐resistant S. aureus infections, offering a mechanism to circumvent prevailing resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biological Sciences & Engineering, Indian Institute of Technology Gandhinagar, Palaj, Gandhinagar, Gujarat, India.
- Centre For Interdisciplinary Research in Basic Sciences, Jamia Millia Islamia, Jamia Nagar, New Delhi, India.
- Department of Biosciences and Bioinformatics, School of Science, Xi'an Jiaotong-Liverpool University, Suzhou, China.
- Department of Biochemistry, Jamia Hamdard, New Delhi, India.
- Sushen Medicamentos Pvt. Ltd., Ahmedabad, Gujarat, India.
- Department of Chemistry, Indian Institute of Technology Gandhinagar, Palaj, Gandhinagar, Gujarat, India.
ORCID-Profile: Bhaskar Datta, Md Imtaiyaz Hassan
Förderung
- Indian Council of Medical Research-Department of Health Research
- Indian Council of Medical Research
Zitieren
APA
Hadiya, R. K., Ashraf, A., Wang, Y., Khan, F. I., Khan, M. A., Renuka, L., Ahmad, S., Noor, S., Shah, K., Datta, B., & Hassan, M. I. (2025). Thiazolyl Benzenesulfonamide Derivative as a Novel Inhibitor of Thymidine Kinase: Promising Therapeutics Against Staphylococcus aureus. Chemistry & Biodiversity. https://doi.org/10.1002/cbdv.202501600
Vancouver
Hadiya RK, Ashraf A, Wang Y, Khan FI, Khan MA, Renuka L, et al. Thiazolyl Benzenesulfonamide Derivative as a Novel Inhibitor of Thymidine Kinase: Promising Therapeutics Against Staphylococcus aureus. Chemistry & Biodiversity. 2025. doi:10.1002/cbdv.202501600
BibTeX
@article{Hadiya2025,
author = {Hadiya, Rajesh K and Ashraf, Anam and Wang, Yuanyuan and Khan, Faez Iqbal and Khan, Mohammad Ali and Renuka, L and Ahmad, Shahbaz and Noor, Saba and Shah, Kaushik and Datta, Bhaskar and Hassan, Md Imtaiyaz},
title = {Thiazolyl Benzenesulfonamide Derivative as a Novel Inhibitor of Thymidine Kinase: Promising Therapeutics Against Staphylococcus aureus},
journal = {Chemistry & Biodiversity},
year = {2025},
doi = {10.1002/cbdv.202501600}
}
EUVIMED